Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Secondary and selected exploratory endpoints of the DESTINY-Breast03 trial of trastuzumab deruxtecan or trastuzumab emtansine in patients with advanced HER2-positive breast cancer are reported, including updated efficacy and safety data after a median follow-up of 41 months.
In an exploratory analysis of the Keynote-361 phase 3 trial that tested immunotherapy and chemotherapy in advanced urothelial carcinoma, different early ctDNA dynamics were observed between the two treatments, and ctDNA levels were associated with response to pembrolizumab, but not to chemotherapy. Anna Maria Ranzoni, in collaboration with the Nature Medicine team.
In a phase 3 randomized controlled trial comparing secondary cytoreduction plus chemotherapy versus chemotherapy alone in patients with relapsed ovarian cancer, the coprimary endpoint of overall survival was not statistically different, but in a prespecified sensitivity analysis adjusted for patients who underwent crossover surgery following tumor relapse, there was an increase in overall survival.
In this phase 1 trial, treatment of patients with ER+HER2− metastatic breast cancer with a selective catalytic inhibitor of the lysine acetyltransferase KAT6 shows a manageable safety profile and encouraging preliminary clinical efficacy.
In a randomized, double-blind, placebo-controlled phase 3 trial, the anti-vascular endothelial growth factor receptor small-molecule inhibitor fruquintinib plus chemotherapy significantly extended progression-free survival, but not overall survival, as second-line therapy in patients with advanced gastric or gastroesophageal junction cancers.
Multimodal approaches combining various numbers of behavioral, neuroimaging and electrophysiological markers improves neuroprognosis performance in clinically unresponsive critical-care patients.
Analyses from the US Department of Veterans Affairs databases reported residual elevated risk and health burden of long COVID at 3 years in hospitalized individuals after SARS-CoV-2 infection.
FDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung cancer, cervical cancer and more.
AI-based three-dimensional genomic mapping reveals a large abundance of cancer precursors in normal pancreatic tissue — prompting new insights and research directions.
A whole-body scanner developed using a permanent 0.05-tesla magnet and deep learning has demonstrated its versatility in imaging various anatomical structures, showcasing its potential to address unmet clinical needs.
T1 mapping noninvasively assesses fibrosis in multiple organs and enables risk stratification of mortality and provides insights into shared and organ-specific pathways underlying fibrosis.
Accumulating data support the systemic benefits of semaglutide (and potentially other GLP-1RA-based therapies) in people with obesity, meaning that cardiologists and other clinicians must become familiar with prescribing them — particularly once market competition makes these drugs more accessible.
In a randomized clinical trial, treatment using a monoclonal antibody targeting interleukin-6 (IL-6) in patients with cardiovascular disease and/or diabetes who were receiving maintenance kidney dialysis reduced levels of inflammatory biomarkers at 12 weeks, including C-reactive protein, paving the way for a phase 3 trial.
In a pre-specified secondary analysis of the SELECT trial, once-weekly subcutaneous semaglutide 2.4 mg in patients with obesity was associated with a 22% reduction in the main 5-component kidney composite endpoint compared to patients on placebo.